Cerus Corp - Company Profile
Powered by
All the data and insights you need on Cerus Corp in one report.
- Save hours of research time and resources with
our up-to-date Cerus Corp Strategy Report
- Understand Cerus Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Cerus Corp (Cerus) is a biomedical products company that focuses on the field of blood transfusion safety. It develops and commercializes Intercept blood system, which reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria, and parasites present in donated blood. The Intercept blood system is for use with blood components including platelets, plasma, and red blood cells. It is also used to produce intercept fibrinogen complex (IFC), and pathogen reduced plasma and cryoprecipitate. The company markets and sells the Intercept blood system through its direct sales force and distributors in several countries including the US, Europe, the Commonwealth of Independent States (CIS), Latin America, the Middle East, and selected countries in other regions. Cerus is headquartered in Concord, California, the US.
Cerus Corp premium industry data and analytics
Products and Services
Products | Brands |
---|---|
- | - |
UVA Illumination Devices | Intercept |
Intercept Blood System for Platelets and Plasma | |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In November, the company entered into an agreement with Bloodbuy to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex through the Bloodbuy online marketplace. |
2022 | Regulatory Approval | In November, the company received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System with seven-day storage. |
2022 | Contracts/Agreements | In May, the company entered into an agreement with Fresenius Kabi for the production of INTERCEPT Blood System sets. |
Competitor Comparison
Key Parameters | Cerus Corp | Grifols SA | Octapharma AG | Kedrion Biopharma Inc | MacoPharma International Gmbh |
---|---|---|---|---|---|
Headquarters | United States of America | Spain | Switzerland | United States of America | Germany |
City | Concord | Barcelona | Lachen | Fort Lee | Langen |
State/Province | California | Barcelona | Schwyz | New Jersey | Hessen |
No. of Employees | 309 | 23,245 | 11,573 | - | - |
Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Daniel N. Swisher Jr. | Chairman | Executive Board | 2013 | 60 |
William M. Greenman | President; Director; Chief Executive Officer | Executive Board | 2011 | 56 |
Kevin D. Green | Vice President - Finance; Chief Financial Officer | Senior Management | 2013 | 51 |
Vivek K. Jayaraman | Chief Operating Officer | Senior Management | 2020 | 48 |
Chrystal N. Menard | General Counsel; Chief Legal Officer | Senior Management | 2012 | 52 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer